Annals of Clinical Biochemistry > Volume 45, Number 4 > Pp. 343-344

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Barth, J. H Articles by Watson, I. D PubMed PubMed Citation Social Bookmarking                      What's this?

Consensus Report

Consensus meeting on reporting glycated haemoglobin and estimated average glucose in the UK: report to the National Director for Diabetes, Department of Health

Julian H Barth¹, Sally M Marshall² and Ian D Watson¹

¹ Association for Clinical Biochemistry; ² School of Clinical Medical Sciences, University of Newcastle-upon-Tyne Medical School, UK

A consensus paper¹ on worldwide standardization of measurement and reporting of glycated haemoglobin (HbA_1c) has been published recently by the American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), International Federation of Clinical Chemistry (IFCC) and Laboratory Medicine and the International Diabetes Federation (IDF). This proposal has accepted that the IFCC Reference Measurement procedure² should be the international method for calibrating all assays used for the measurement of glycated haemoglobin. The consensus proposed five points, which are reproduced in Box 1.

Box 1 ADA, EASD, IFCC, IDF 2007 Consensus1 HbA1c test results should be standardized worldwide, including the reference system and results reporting. The new IFCC reference system is the only valid anchor to implement standardization of the HbA1c measurement. HbA1c test results should be standardized worldwide, including the reference system and results reporting. The new IFCC reference system is the only valid anchor to implement standardization of the HbA1c measurement. HbA1c results are to be reported worldwide in IFCC units (mmol/mol) and derived NGSP units (%), using the IFCC-NGSP master equation. If the ongoing ‘average plasma glucose study’ fulfils its a priori specified criteria, an ADAG value calculated from the HbA1c result will also be reported as an interpretation of the HbA1c results. Glycaemic goals appearing in clinical guidelines should be expressed as IFCC units, derived NGSP units and as ADAG.

 

A meeting convened at the request of Dr Sue Roberts, National Director for Diabetes, was held in London on 23 January 2008. Representatives of 18 professional organizations and representatives of the diagnostic industry involved in the management of people with diabetes as well as patients with diabetes (Box 2) attended to discuss these proposals and how they should be incorporated into clinical practice in the UK.

1. HbA_1c test results should be standardized worldwide, including the reference system and results reporting.
   
2. The new IFCC reference system is the only valid anchor to implement standardization of the HbA_1c measurement.
   

These two points were universally accepted and, indeed, they were first proposed at an earlier consensus held in London in 2000.³

(3) HbA_1c results are to be reported worldwide in IFCC units (mmol/mol) and derived National Glycohemoglobin Standardization Program (NGSP) units (%), using the IFCC-NGSP master equation.

Box 2 Professional organizations represented at the London meeting Association for Clinical Biochemistry Association of Clinical Pathologists Association of British Clinical Diabetologists Australian Association of Clinical Biochemists British In-Vitro Diagnostics Association Department of Health of England Diabetes UK European Federation of Clinical Chemistry International Diabetes Foundation International Federation of Clinical Chemistry and Laboratory Medicine Primary Care Diabetes Society Royal College of General Practitioners Royal College of Nursing Royal College of Obstetricians and Gynaecologists Royal College of Pathologists Royal College of Physicians UK National External Quality Assessment Scheme (UK NEQAS) Wales External Quality Assessment Scheme (WEQAS)

 

There was an agreement that it was necessary for glycated haemoglobin to be standardized to the IFCC Reference Measurement procedure but there was a concern regarding the introduction of a dual reporting system including new units with which patients and clinicians were unfamiliar. It was felt that there was a real risk that patient control would deteriorate due to lack of understanding, particularly with an unheralded change to IFCC units. It was agreed that dual reporting would be necessary for a considerable period until both unitary systems were understood. However, this should only occur after extensive educational programmes had been performed. Moreover, it must be ensured that these programmes will reach all the appropriate health-care professionals as well as patients.

(4) If the ongoing ‘average plasma glucose study’ fulfils its a priori specified criteria, an HbA_1c-derived average glucose (ADAG) value calculated from the HbA_1c result will also be reported as an interpretation of the HbA_1c results.

A report of the preliminary findings of the ADAG study was presented by one of the study investigators.⁴ Data were presented on approximately two-thirds of the subjects, although it was stated that it was anticipated at this stage that the final results would not be different. The group attending uniformly felt that there was insufficient information regarding entry criteria, study design and data analysis on which to accept any conclusions at this stage and that further studies validating the findings from the ADAG study would be required before implementation could be considered.

The conceptual benefits of reporting glycated haemoglobin in terms that patients understand was accepted for patients who measure their own blood glucose concentrations, despite the fact that no patient survey had been performed to study this aspect. However, there was a concern that it would not be beneficial for the vast majority of patients with diabetes who have type 2 disease and who do not routinely measure capillary glucose.

Moreover, there was a concern that the formula for calculating estimated average glucose (eAG) would give a different value than the capillary (finger-prick) samples used for daily monitoring. Overall, it was felt that due to issues raised about the study design and the clinical applicability of the eAG measurement in practice, it was not possible to consider implementing this recommendation in the UK.

(5) Glycaemic goals appearing in clinical guidelines should be expressed as IFCC units, derived NGSP units and as ADAG.

There was a general agreement that reporting a single measurement in three different formats was considered to be unacceptably complicated.

There was a mention of the need for a consistent international measurement for the monitoring of diabetes in a world with huge population mobility to ensure that all patients would have optimal care.

It was felt that eAG was an interesting concept that had the potential to help patients with diabetes improve their understanding of diabetes and therefore improve their health. Participants recommended that studies of eAG should be performed in the UK and that these studies should include patient populations who have been excluded from ADAG. These include children, pregnant women, the elderly and ethnic populations.

	Summary recommendations for the UK

Top Summary recommendations for the... REFERENCES

 

• HbA_1c test results should be standardized using the new IFCC Reference Measurement procedure.
  
• An extensive education programme should be developed urgently for all health-care professionals and people with diabetes to help the understanding and interpretation of the new IFCC units. Provision of this programme will require considerable resources.
  
• HbA_1c results should be reported in both IFCC units (mmol/mol) and derived NGSP units (%) (synonymous with Diabetes Control and Complications Trial [DCCT]), using the IFCC-NGSP master equation for the time being
  
• There is currently insufficient experimental evidence to support the introduction of eAG.
  
• Further research into the individual utility of eAG and of its use in all groups of individuals with diabetes is required in order to determine what role reporting of eAG has in clinical practice.
  

	REFERENCES

Top Summary recommendations for the... REFERENCES

 

1. ADA, EASD, IFCC Consensus Committee. Consensus statement on the worldwide standardisation of the HbA_1c measurement. Diabetologia 2007;50:2042–3[Medline]
2. Finke A Kobold U Hoelzel W Weycamp C Jeppsson JO Miedema K. Preparation of a candidate primary reference material for the international standardisation of HbA_1c determinations. Clin Chem Lab Med 1998;36:299–308[Medline]
3. Marshall SM Barth JH. Standardisation of HbA_1c measurements – a consensus statement. Ann Clin Biochem 2000;37:45–56; Diabet Med 2000;17:5–6[Free Full Text]
4. See http://www.easd-lectures.org/amsterdam/index.php?menu=view&id=201 (accessed 24 February 2008)

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Barth, J. H Articles by Watson, I. D PubMed PubMed Citation Social Bookmarking                      What's this?